FDx Advisors Inc. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,868 shares of the biopharmaceutical company’s stock after selling 432 shares during the period. FDx Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,729,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Alpha Windward LLC lifted its stake in Regeneron Pharmaceuticals by 0.3% during the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1 shares in the last quarter. Regentatlantic Capital LLC lifted its stake in Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 5 shares in the last quarter. Capital Planning Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 2.1% during the 2nd quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 12 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in Regeneron Pharmaceuticals by 1.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 12 shares in the last quarter. Finally, Princeton Capital Management Inc. raised its position in Regeneron Pharmaceuticals by 0.6% in the 2nd quarter. Princeton Capital Management Inc. now owns 2,511 shares of the biopharmaceutical company’s stock valued at $1,233,000 after purchasing an additional 15 shares in the last quarter. 67.80% of the stock is currently owned by hedge funds and other institutional investors.

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman P Roy Vagelos sold 10,986 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $470.17, for a total value of $5,165,287.62. Following the transaction, the chairman now directly owns 329,543 shares of the company’s stock, valued at approximately $154,941,232.31. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 88,942 shares of company stock valued at $42,064,076. 10.80% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at $393.62 on Tuesday. The stock has a market capitalization of $43,346.87, a price-to-earnings ratio of 35.03, a P/E/G ratio of 1.56 and a beta of 1.56. Regeneron Pharmaceuticals, Inc. has a 1-year low of $340.09 and a 1-year high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s revenue was up 23.0% on a year-over-year basis. During the same period in the previous year, the firm posted $3.13 earnings per share. analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.77 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “FDx Advisors Inc. Decreases Position in Regeneron Pharmaceuticals, Inc. (REGN)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/14/fdx-advisors-inc-decreases-position-in-regeneron-pharmaceuticals-inc-regn.html.

A number of research firms have issued reports on REGN. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $425.00 price target (down previously from $473.00) on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 9th. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Citigroup Inc. reaffirmed a “buy” rating and issued a $480.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 9th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price target on the stock in a research report on Wednesday, August 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $580.00 price target (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $481.49.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.